Omega-3 Fatty Acids and Cognitive Function — A Research Summary

DHA (docosahexaenoic acid) is the dominant structural fatty acid in brain gray matter, constituting approximately 15-20% of total fatty acid content in the cerebral cortex. It is incorporated into neuronal cell membranes, where it influences membrane fluidity, receptor function, and synaptic transmission. EPA (eicosapentaenoic acid) has potent anti-inflammatory effects and influences neurotransmitter metabolism, particularly serotonin and dopamine pathways.

At the molecular level, omega-3s modulate neuroinflammation by competing with arachidonic acid for cyclooxygenase enzymes, shifting prostaglandin production toward less inflammatory variants. In animal models, DHA supplementation increases BDNF (brain-derived neurotrophic factor) and promotes dendritic branching. These mechanisms are biologically plausible and well-established in cell and animal research.

The picture from human RCTs is more complicated than the mechanism suggests. For prevention of cognitive decline in cognitively normal older adults, large trials including the AREDS2 study (4,203 participants, 5 years) and the VITACOG trial found no significant benefit from omega-3 supplementation on cognitive outcomes. The MAPT trial in France (1,680 participants, 3 years) also found no benefit from omega-3 alone, though there was a non-significant trend in participants with low baseline DHA levels.

For people with mild cognitive impairment, results have been more mixed but slightly more encouraging. A 2016 Cochrane review concluded that evidence was insufficient to draw conclusions about omega-3 and dementia prevention, largely due to heterogeneity across trials.

Where the evidence is more consistent: omega-3 supplementation clearly benefits people with low baseline DHA levels (often vegetarians and older adults with poor fish intake), and has established benefits for depression — a major modifiable risk factor for cognitive decline. Several meta-analyses confirm antidepressant effects at doses of 1-2g EPA/day.

Promising. The biological plausibility is strong, and observational studies consistently show associations between higher omega-3 intake and better cognitive outcomes. But RCT evidence for prevention in cognitively normal people is underwhelming. The most plausible interpretation: omega-3s protect against deficiency and reduce neuroinflammation, but supplementing people who already have adequate levels may not produce detectable additional benefit.

The most promising intervention target may be people with low baseline DHA (detectable through a blood test) or those with elevated inflammatory markers, rather than unselected older adults.

Positive trials for depression typically use 1-2g EPA per day. Trials for cognitive outcomes have used a range of doses, typically 0.9-3.5g combined EPA+DHA daily. Standard fish oil capsules contain 300-600mg combined EPA+DHA — meaning 2-4 capsules per day to reach research-relevant doses.

Algae-derived DHA provides a plant-based alternative at comparable doses. Krill oil has higher bioavailability per gram but is more expensive per equivalent dose.

Omega-3s have an excellent safety profile at doses under 3g/day. At higher doses, mild anticoagulant effects occur — relevant for people on warfarin or antiplatelet medications. Fish oil can cause fishy burps (largely solved by enteric-coated formulations or freezing capsules). High-dose fish oil can raise LDL cholesterol in some individuals.

Omega-3s are worth taking if you eat little fatty fish (salmon, mackerel, sardines, herring less than 2-3 times per week), have elevated inflammatory markers, or have depression or mood instability. For cognitively normal adults with adequate dietary intake, the evidence for additional cognitive benefit from supplementation is weak.

If you do supplement, a baseline DHA blood level (available through services like OmegaQuant) tells you whether supplementation is actually changing your status — more useful than guessing.